1. Incorporation of uncertainty in health economic modelling studies

   • Anthony O’Hagan
   • Christopher McCabe
   • Andrew Willan

   Leading Article 17 September 2012 Pages: 529 - 536

   

2. Health utilities in Alzheimer’s disease and implications for cost-effectiveness analysis

   • Peter J. Neumann

   Commentary 17 September 2012 Pages: 537 - 541

   

3. The economics of topical immunomodulators for the treatment of atopic dermatitis

   • William Abramovits
   • Mark Boguniewicz
   • Kuo B. Tong

   Review Article 17 September 2012 Pages: 543 - 566

   

4. Remission from depression

   • Donald Han
   • Edward C. Y. Wang

   Review Article 17 September 2012 Pages: 567 - 581

   

5. Bipolar disorder and health-related quality of life

   • Dennis A. Revicki
   • Louis S. Matza
   • Andrew Lloyd

   Review Article 17 September 2012 Pages: 583 - 594

   

6. Pharmacoeconomic evaluation of antidepressants

   • Sheikh Usman Iqbal
   • Mark Prashker

   Review Article 17 September 2012 Pages: 595 - 606

   

7. The cost effectiveness of infliximab for severe treatment-resistant rheumatoid arthritis in the UK

   • Marco Barbieri
   • John B. Wong
   • Michael Drummond

   Original Research Article 17 September 2012 Pages: 607 - 618

   

8. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease

   • Michael Spencer
   • Andrew H. Briggs
   • Laureen Rance

   Original Research Article 17 September 2012 Pages: 619 - 637